Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 119

1.

Defining optimal dosing of ciprofloxacin in patients with septic shock.

Roberts JA, Alobaid AS, Wallis SC, Perner A, Lipman J, Sjövall F.

J Antimicrob Chemother. 2019 Feb 26. pii: dkz069. doi: 10.1093/jac/dkz069. [Epub ahead of print]

PMID:
30809648
2.

Recovery rates of combination antibiotic therapy using in vitro microdialysis simulating in vivo conditions.

Dhanani JA, Parker SL, Lipman J, Wallis SC, Cohen J, Fraser J, Barnett A, Chew M, Roberts JA.

J Pharm Anal. 2018 Dec;8(6):407-412. doi: 10.1016/j.jpha.2018.07.003. Epub 2018 Jul 6.

3.

Ex Vivo Characterization of Effects of Renal Replacement Therapy Modalities and Settings on Pharmacokinetics of Meropenem and Vaborbactam.

Sime FB, Pandey S, Karamujic N, Parker S, Alexander E, Loutit J, Durso S, Griffith D, Lipman J, Wallis SC, Roberts JA.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e01306-18. doi: 10.1128/AAC.01306-18. Print 2018 Oct.

4.

A pharmacokinetic case study of intravenous posaconazole in a critically ill patient with hypoalbuminaemia receiving continuous venovenous haemodiafiltration.

Sime FB, Stuart J, Butler J, Starr T, Wallis SC, Pandey S, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2018 Oct;52(4):506-509. doi: 10.1016/j.ijantimicag.2018.07.008. Epub 2018 Jul 19.

PMID:
30031203
5.

A research pathway for the study of the delivery and disposition of nebulised antibiotics: an incremental approach from in vitro to large animal models.

Dhanani JA, Cohen J, Parker SL, Chan HK, Tang P, Ahern BJ, Khan A, Bhatt M, Goodman S, Diab S, Chaudhary J, Lipman J, Wallis SC, Barnett A, Chew M, Fraser JF, Roberts JA.

Intensive Care Med Exp. 2018 Jul 11;6(1):17. doi: 10.1186/s40635-018-0180-7.

6.

Optimised dosing of vancomycin in critically ill Indigenous Australian patients with severe sepsis.

Tsai D, Stewart PC, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Anaesth Intensive Care. 2018 Jul;46(4):374-380.

PMID:
29966110
7.

Population Pharmacokinetics of Periarticular Ketorolac in Adult Patients Undergoing Total Hip or Total Knee Replacement Surgery.

Gurunathan U, Parker SL, Maguire R, Ramdath D, Bijoor M, Wallis SC, Roberts JA.

Anesth Analg. 2018 Apr 23. doi: 10.1213/ANE.0000000000003377. [Epub ahead of print]

PMID:
29697507
8.

Characterisation of 40 mg/ml and 100 mg/ml tobramycin formulations for aerosol therapy with adult mechanical ventilation.

Dhanani JA, Tang P, Wallis SC, Parker SL, Pandey P, Fraser JF, Cohen J, Barnett A, Roberts JR, Chan HK.

Pulm Pharmacol Ther. 2018 Jun;50:93-99. doi: 10.1016/j.pupt.2018.04.006. Epub 2018 Apr 18.

PMID:
29679678
9.

Pharmacokinetics of Intravenous Posaconazole in Critically Ill Patients.

Sime FB, Stuart J, Butler J, Starr T, Wallis SC, Pandey S, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2018 May 25;62(6). pii: e00242-18. doi: 10.1128/AAC.00242-18. Print 2018 Jun.

10.

Evidence of clinical response and stability of Ceftolozane/Tazobactam used to treat a carbapenem-resistant Pseudomonas Aeruginosa lung abscess on an outpatient antimicrobial program.

Stewart A, Roberts JA, Wallis SC, Allworth AM, Legg A, McCarthy KL.

Int J Antimicrob Agents. 2018 Jun;51(6):941-942. doi: 10.1016/j.ijantimicag.2018.02.008. Epub 2018 Feb 19. No abstract available.

PMID:
29471023
11.

Optimization and Evaluation of Piperacillin-Tobramycin Combination Dosage Regimens against Pseudomonas aeruginosa for Patients with Altered Pharmacokinetics via the Hollow-Fiber Infection Model and Mechanism-Based Modeling.

Yadav R, Rogers KE, Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e00078-18. doi: 10.1128/AAC.00078-18. Print 2018 May.

12.

Clinical application of microsampling versus conventional sampling techniques in the quantitative bioanalysis of antibiotics: a systematic review.

Guerra Valero YC, Wallis SC, Lipman J, Stove C, Roberts JA, Parker SL.

Bioanalysis. 2018 Mar;10(6):407-423. doi: 10.4155/bio-2017-0269. Epub 2018 Feb 16. Review.

PMID:
29451394
13.

Incremental research approach to describing the pharmacokinetics of ciprofloxacin during extracorporeal membrane oxygenation.

Sinnah F, Shekar K, Abdul-Aziz MH, Buscher H, Diab SD, Fisquet S, Fung YL, McDonald CI, Reynolds C, Rudham S, Wallis SC, Welch S, Xie J, Fraser JF, Roberts JA; ASAP ECMO investigators.

Crit Care Resusc. 2017 Oct;19(Suppl 1):8-14.

PMID:
29084496
14.

A UHPLC-MS/MS method for the simultaneous determination of piperacillin and tazobactam in plasma (total and unbound), urine and renal replacement therapy effluent.

Naicker S, Guerra Valero YC, Ordenez Meija JL, Lipman J, Roberts JA, Wallis SC, Parker SL.

J Pharm Biomed Anal. 2018 Jan 30;148:324-333. doi: 10.1016/j.jpba.2017.10.023. Epub 2017 Oct 25.

PMID:
29080413
15.

Maximally effective dosing regimens of meropenem in patients with septic shock.

Sjövall F, Alobaid AS, Wallis SC, Perner A, Lipman J, Roberts JA.

J Antimicrob Chemother. 2018 Jan 1;73(1):191-198. doi: 10.1093/jac/dkx330.

PMID:
28961812
16.

Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients.

Roger C, Cotta MO, Muller L, Wallis SC, Lipman J, Lefrant JY, Roberts JA.

Int J Antimicrob Agents. 2017 Aug;50(2):227-231. doi: 10.1016/j.ijantimicag.2017.03.018. Epub 2017 Jul 6.

PMID:
28689876
17.

A validated UHPLC-MS/MS method for the measurement of riluzole in plasma and myocardial tissue samples.

Parker SL, Guerra Valero YC, Lipman J, Weiss S, Smith C, Russell L, Smith P, Roberts JA, Wallis SC.

Biomed Chromatogr. 2017 Dec;31(12). doi: 10.1002/bmc.4030. Epub 2017 Jul 10.

PMID:
28623867
18.

An LC-MS/MS method to determine vancomycin in plasma (total and unbound), urine and renal replacement therapy effluent.

Parker SL, Guerra Valero YC, Ordóñez Mejia JL, Roger C, Lipman J, Roberts JA, Wallis SC.

Bioanalysis. 2017 Jun;9(12):911-924. doi: 10.4155/bio-2017-0019. Epub 2017 Jun 15.

PMID:
28617036
19.

Comparative total and unbound pharmacokinetics of cefazolin administered by bolus versus continuous infusion in patients undergoing major surgery: a randomized controlled trial.

Naik BI, Roger C, Ikeda K, Todorovic MS, Wallis SC, Lipman J, Roberts JA.

Br J Anaesth. 2017 Jun 1;118(6):876-882. doi: 10.1093/bja/aex026.

20.

Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model.

Bergen PJ, Bulitta JB, Kirkpatrick CMJ, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Nation RL, Lipman J, Roberts JA, Landersdorfer CB.

Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02642-16. doi: 10.1128/AAC.02642-16. Print 2017 May.

21.

Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Mejia JL, Roberts MS, Roger C, Udy AA, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01276-16. doi: 10.1128/AAC.01276-16. Print 2017 Mar.

22.

Caspofungin Population Pharmacokinetics in Critically Ill Patients Undergoing Continuous Veno-Venous Haemofiltration or Haemodiafiltration.

Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Brüggemann RJ, Lefrant JY, Roberts JA.

Clin Pharmacokinet. 2017 Sep;56(9):1057-1068. doi: 10.1007/s40262-016-0495-z.

PMID:
28035589
23.

Total and unbound ceftriaxone pharmacokinetics in critically ill Australian Indigenous patients with severe sepsis.

Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2016 Dec;48(6):748-752. doi: 10.1016/j.ijantimicag.2016.09.021. Epub 2016 Nov 4.

PMID:
27838278
24.

Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.

Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2016 Nov;48(5):542-546. doi: 10.1016/j.ijantimicag.2016.08.015. Epub 2016 Sep 29.

PMID:
27771187
25.

Pharmacokinetics of Piperacillin in Critically Ill Australian Indigenous Patients with Severe Sepsis.

Tsai D, Stewart P, Goud R, Gourley S, Hewagama S, Krishnaswamy S, Wallis SC, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7402-7406. Print 2016 Dec.

26.

Effect of time on recovery of plasma microsamples for the quantitative determination of vancomycin.

Parker SL, Guerra Valero YC, Lipman J, Roberts JA, Wallis SC.

Bioanalysis. 2016 Nov;8(21):2235-2242. Epub 2016 Sep 26.

PMID:
27665940
27.

Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients.

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Mejia JL, Roberts MS, Sinnollareddy MG, Roger C, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2016 Oct 21;60(11):6550-6557. doi: 10.1128/AAC.01088-16. Print 2016 Nov.

28.

Influence of Renal Replacement Modalities on Amikacin Population Pharmacokinetics in Critically Ill Patients on Continuous Renal Replacement Therapy.

Roger C, Wallis SC, Muller L, Saissi G, Lipman J, Lefrant JY, Roberts JA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4901-9. doi: 10.1128/AAC.00828-16. Print 2016 Aug.

29.

Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.

Bergen PJ, Bulitta JB, Kirkpatrick CM, Rogers KE, McGregor MJ, Wallis SC, Paterson DL, Lipman J, Roberts JA, Landersdorfer CB.

J Antimicrob Chemother. 2016 Sep;71(9):2509-20. doi: 10.1093/jac/dkw153. Epub 2016 May 26.

PMID:
27231278
30.

Effect of Obesity on the Population Pharmacokinetics of Meropenem in Critically Ill Patients.

Alobaid AS, Wallis SC, Jarrett P, Starr T, Stuart J, Lassig-Smith M, Ordóñez Mejia JL, Roberts MS, Lipman J, Roberts JA.

Antimicrob Agents Chemother. 2016 Jul 22;60(8):4577-84. doi: 10.1128/AAC.00531-16. Print 2016 Aug.

31.

Is there a role for microsampling in antibiotic pharmacokinetic studies?

Parker SL, Dorofaeff T, Lipman J, Ballot DE, Bandini RM, Wallis SC, Roberts JA.

Expert Opin Drug Metab Toxicol. 2016 Jun;12(6):601-14. doi: 10.1080/17425255.2016.1178238. Epub 2016 May 3. Review.

PMID:
27087416
32.

Comparison of equal doses of continuous venovenous haemofiltration and haemodiafiltration on ciprofloxacin population pharmacokinetics in critically ill patients.

Roger C, Wallis SC, Louart B, Lefrant JY, Lipman J, Muller L, Roberts JA.

J Antimicrob Chemother. 2016 Jun;71(6):1643-50. doi: 10.1093/jac/dkw043. Epub 2016 Mar 7.

PMID:
26957490
33.

SaMpling Antibiotics in Renal Replacement Therapy (SMARRT): an observational pharmacokinetic study in critically ill patients.

Roberts JA, Choi GY, Joynt GM, Paul SK, Deans R, Peake S, Cole L, Stephens D, Bellomo R, Turnidge J, Wallis SC, Roberts MS, Roberts DM, Lassig-Smith M, Starr T, Lipman J.

BMC Infect Dis. 2016 Mar 1;16:103. doi: 10.1186/s12879-016-1421-6.

34.

Pharmacokinetics of Intraperitoneal Cefalothin and Cefazolin in Patients Being Treated for Peritoneal Dialysis-Associated Peritonitis.

Roberts DM, Ranganathan D, Wallis SC, Varghese JM, Kark A, Lipman J, Roberts JA.

Perit Dial Int. 2016 Jul-Aug;36(4):415-20. doi: 10.3747/pdi.2015.00008. Epub 2016 Jan 13.

35.

Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.

Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, Rai V, Wong KK, Hasan MS, Abd Rahman AN, Jamal JA, Wallis SC, Lipman J, Staatz CE, Roberts JA.

Intensive Care Med. 2016 Oct;42(10):1535-1545. doi: 10.1007/s00134-015-4188-0. Epub 2016 Jan 11.

PMID:
26754759
36.

Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.

Shekar K, Roberts JA, Barnett AG, Diab S, Wallis SC, Fung YL, Fraser JF.

Crit Care. 2015 Dec 15;19:437. doi: 10.1186/s13054-015-1151-y.

37.

Population pharmacokinetics of linezolid in critically ill patients on renal replacement therapy: comparison of equal doses in continuous venovenous haemofiltration and continuous venovenous haemodiafiltration.

Roger C, Muller L, Wallis SC, Louart B, Saissi G, Lipman J, Lefrant JY, Roberts JA.

J Antimicrob Chemother. 2016 Feb;71(2):464-70. doi: 10.1093/jac/dkv349. Epub 2015 Nov 3.

PMID:
26538503
38.

Stability of Antibiotics for Intraperitoneal Administration in Extraneal 7.5% Icodextrin Peritoneal Dialysis Bags (STAB Study).

Ranganathan D, Naicker S, Wallis SC, Lipman J, Ratanjee SK, Roberts JA.

Perit Dial Int. 2016 Jul-Aug;36(4):421-6. doi: 10.3747/pdi.2015.00062. Epub 2015 Oct 22.

39.

Population Pharmacokinetics of Doripenem in Critically Ill Patients with Sepsis in a Malaysian Intensive Care Unit.

Abdul-Aziz MH, Abd Rahman AN, Mat-Nor MB, Sulaiman H, Wallis SC, Lipman J, Roberts JA, Staatz CE.

Antimicrob Agents Chemother. 2015 Oct 19;60(1):206-14. doi: 10.1128/AAC.01543-15. Print 2016 Jan.

40.

Quantitative bioanalytical validation of fosfomycin in human whole blood with volumetric absorptive microsampling.

Parker SL, Roberts JA, Lipman J, Wallis SC.

Bioanalysis. 2015 Oct;7(19):2585-95. doi: 10.4155/bio.15.173. Epub 2015 Oct 16.

PMID:
26470832
41.

Is prolonged infusion of piperacillin/tazobactam and meropenem in critically ill patients associated with improved pharmacokinetic/pharmacodynamic and patient outcomes? An observation from the Defining Antibiotic Levels in Intensive care unit patients (DALI) cohort.

Abdul-Aziz MH, Lipman J, Akova M, Bassetti M, De Waele JJ, Dimopoulos G, Dulhunty J, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Roberts JA; DALI Study Group.

J Antimicrob Chemother. 2016 Jan;71(1):196-207. doi: 10.1093/jac/dkv288. Epub 2015 Oct 3.

PMID:
26433783
42.

An UHPLC-MS/MS method for the simultaneous determination of ampicillin and sulbactam in human plasma and urine.

Parker SL, Adnan S, Ordóñez Meija JL, Paterson DL, Lipman J, Roberts JA, Wallis SC.

Bioanalysis. 2015 Sep;7(18):2311-2319. doi: 10.4155/bio.15.143. Epub 2015 Sep 23.

PMID:
26395242
43.

Determination of Cefalothin and Cefazolin in Human Plasma, Urine and Peritoneal Dialysate by UHPLC-MS/MS: application to a pilot pharmacokinetic study in humans.

Parker SL, Guerra Valero YC, Roberts DM, Lipman J, Roberts JA, Wallis SC.

Biomed Chromatogr. 2016 Jun;30(6):872-9. doi: 10.1002/bmc.3622. Epub 2015 Oct 28.

PMID:
26394804
44.

Pharmacokinetics of a novel dosing regimen of oral melatonin in critically ill patients.

Bellapart J, Roberts JA, Appadurai V, Wallis SC, Nuñez-Nuñez M, Boots RJ.

Clin Chem Lab Med. 2016 Mar;54(3):467-72. doi: 10.1515/cclm-2015-0323.

PMID:
26351927
45.

Can we use an ex vivo continuous hemofiltration model to describe the adsorption and elimination of meropenem and piperacillin?

Jamal JA, Udy AA, Wallis SC, Ranganathan D, McWhinney BC, Ungerer JP, Lipman J, Roberts JA.

Int J Artif Organs. 2015 Aug;38(8):419-24. doi: 10.5301/ijao.5000422. Epub 2015 Aug 4.

PMID:
26349527
46.

A validated method for the quantification of fosfomycin on dried plasma spots by HPLC-MS/MS: application to a pilot pharmacokinetic study in humans.

Parker SL, Lipman J, Dimopoulos G, Roberts JA, Wallis SC.

J Pharm Biomed Anal. 2015 Nov 10;115:509-14. doi: 10.1016/j.jpba.2015.07.013. Epub 2015 Jul 19.

PMID:
26299527
47.

Assays for therapeutic drug monitoring of β-lactam antibiotics: A structured review.

Carlier M, Stove V, Wallis SC, De Waele JJ, Verstraete AG, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2015 Oct;46(4):367-75. doi: 10.1016/j.ijantimicag.2015.06.016. Epub 2015 Jul 29. Review.

PMID:
26271599
48.

Population Pharmacokinetics of Fosfomycin in Critically Ill Patients.

Parker SL, Frantzeskaki F, Wallis SC, Diakaki C, Giamarellou H, Koulenti D, Karaiskos I, Lipman J, Dimopoulos G, Roberts JA.

Antimicrob Agents Chemother. 2015 Oct;59(10):6471-6. doi: 10.1128/AAC.01321-15. Epub 2015 Aug 3.

49.

Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study.

Shekar K, Roberts JA, Mcdonald CI, Ghassabian S, Anstey C, Wallis SC, Mullany DV, Fung YL, Fraser JF.

Crit Care. 2015 Apr 14;19:164. doi: 10.1186/s13054-015-0891-z.

50.

Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study.

Sinnollareddy MG, Roberts JA, Lipman J, Akova M, Bassetti M, De Waele JJ, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Dimopoulos G; DALI Study authors.

Crit Care. 2015 Feb 4;19:33. doi: 10.1186/s13054-015-0758-3.

Supplemental Content

Loading ...
Support Center